Organization
McGill University Health Center
25 abstracts
4 posters
Abstract
Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Auckland City Hospital and University of Auckland, Auckland, New Zealand,
Abstract
PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study.Org: McGill University Health Center, Jewish General Hospital Stroll Cancer Prevention Centre, Montréal, QC, Canada, McGill University Department of Human Genetics, Montreal, QC, Canada,
Abstract
Circulating tumor DNA detection after neoadjuvant chemotherapy and prediction of distant relapse free survival, local recurrence, and distant recurrence in triple-negative breast cancer in the TRICIA study.Org: Lady Davis Institute of the Jewish General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada, Canada, Jewish General Hospital-Sir Mortimer B. Davis Jewish General Hospital,
Abstract
Outcomes of very young women and adolescent (VYWAA) with breast cancer (BC) in rural and urban Saskatchewan: A population-based cohort study.Org: McGill University Health Center, University of Saskatchewan, Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Allan Blair Cancer Center,
Abstract
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.Org: Division of Urologic Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Center, Toronto, ON, Canada, Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada, University of Western Ontario, London, ON, Canada, Manitoba Prostate Cancer, University of Manitoba, Winnipeg, MB, Canada, CancerCare Manitoba, Winnipeg, MB, Canada, McGill University Health Center, Montreal, QC, Canada, Department of Urology, Dalhousie University, Halifax, NS, Canada, Queen's University, Kingston, ON, Canada, St. Josephs Healthcare, McMaster University, Hamilton, ON, Canada, Northern Alberta Urology Clinic, Edmonton, AB, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Ottawa Hospital, Ottawa, ON, Canada, CIUSSS de l'Estrie – CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, St. Vincent's Hospital Sydney, Sydney, NSW, Australia, Princess Margaret Cancer Centre, University Health Network, Toronto Allergy and Asthma Centre, Oncotelic,
Abstract
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Org: Université de Montréal, McGill University Health Center, Department of Medical Oncology, Institut du Cancer de Montpellier, Institut de Génomique fonctionnelle, CNRS, University of MontpellierOncology, Institute of Oncology Ljubljana,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
How reliable are post-mastectomy breast reconstruction videos on YouTube?Org: McGill University Health Center, University of Calgary, McGill University Health Centre Research Institute, St Mary's Research Centre,
Abstract
Clinical activity of mitogen-activated protein kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers: A systematic review and meta-analysis.Org: McGill University Health Center, Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS Fondazione Pascale, Memorial Sloan Kettering Cancer Center, Department of Pathology, Memorial Sloan Kettering Cancer Center,
Abstract
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).Org: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, University of Victoria, Victoria, BC, Canada, Canadian Cancer Society, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Patient Partner, Toronto, ON, Canada, University of Alberta, Edmonton, AB, Canada, BC Cancer/ University of British Columbia, Vancouver, BC, Canada, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Department of Medicine, Icahn School of Medicine at Mount Sinai, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre,
Abstract
Perioperative immunochemotherapy (mDCF + avelumab) in locally advanced gastro-esophageal adenocarcinoma: A phase II trial.Org: McGill University Health Center, Montréal, QC, Canada, QC Kinetix, Canada's Michael Smith Genome Sciences Centre, Research Institute of McGill University Health Centre,
Abstract
The impact of genetic predisposition to depression on quality of life in patients with head and neck cancer immediately post-treatment: A longitudinal study.Org: McGill University Health Center, McGill University - Lady Davis Institute for Medical Research, Jewish General Hospital Stroll Cancer Prevention Centre, Yale University,
Abstract
A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.Org: Sunnybrook Hospital, Royal Victoria Hospital/Glen Site/Cedar Cancer Centre, Department of Surgery, University of Ottawa-Ottawa General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Lady Davis Institute, McGill University,
Abstract
Importance of DICER1 pathogenic variants in non-small cell lung cancer.Org: Mayo Clinic Alix School of Medicine, Caris Life Sciences, Irving, TX, McGill University Health Center, University of Toronto, Mayo Clinic Arizona, Phoenix, AZ,
Abstract
GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of ovarian cancer.Org: AOA Dx Inc, Lady Davis Institute-Jewish General Hospital, McGill University Health Center, University of Montreal Hospital Centre (CRCHUM), University of Montreal,
Abstract
The safety of seasonal influenza vaccination among patients prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.Org: ICES, London Regional Cancer Program, Schulich School of Medicine and Dentistry, McGill University Health Center, Université de Sherbrooke,
Abstract
The impact of COVID-19 on the survival outcome of lung cancer at a Canadian academic centre: A real-world data analysis.Org: Jewish General Hospital Stroll Cancer Prevention Centre, Lady Davis Institute of the Jewish General Hospital, McGill University Health Center,
Abstract
Quantitation of the PD-1/PD-L1 axis in non-small cell lung cancer by immuno-multiple reaction monitoring.Org: Lady Davis Institute & McGill University, Manitoba Centre for Proteomics and Systems Biology, McGill University - Lady Davis Institute for Medical Research, Jewish General Hospital Stroll Cancer Prevention Centre, Lady Davis Institute of the Jewish General Hospital,
Abstract
An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.Org: McGill University Health Center, The Second Affiliated Hospital Of Nanchang University, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center,
Abstract
ASSOCIATION OF LUNG IMAGING PATTERN WITH PROGNOSIS AND IMMUNOSUPPRESSION RESPONSE IN CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASEOrg: McGill University Health Center, Saint James Hospital, McMaster University and Juravinski Cancer Centre, University of Montreal, University of Calgary,
Abstract
ACCESS TO TREATMENT FOR RAYNAUD’S PHENOMENON AND DIGITAL ULCERS FOR PATIENTS WITH SYSTEMIC SCLEROSIS DOESN’T FOLLOW EULAR/EUSTAR GUIDELINESOrg: Western University, Medicine and Frontier Science Center of Disease Molecular Network, McGill University Health Center, Rheumatology,
Abstract
ASSOCIATION BETWEEN SERUM BIOMARKERS OF CARTILAGE TURNOVER AND RADIOGRAPHIC AND SYMPTOMATIC PROGRESSION IN AN EARLY POLYARTICULAR INFLAMMATORY ARTHRITIS COHORTOrg: Department of Medicine, University of Alberta, Alberta, Canada, University of Sherbrooke, Fleurimont, McGill University Health Center, Ibex Pharmaceuticals,
Abstract
AUTOIMMUNE DISEASES IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Bristol-Myers Squibb, University of British Columbia, Mu Sigma, McGill University Health Center,
Abstract
BASELINE CHARACTERISTICS OF PATIENTS RECEIVING BIOLOGIC AND TRADITIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) THERAPY IN ONTARIO: RESULTS FROM THE ONTARIO BIOLOGICS RESEARCH INITIATIVE Org: University of Toronto, University Health Network, Division of Clinical Epidemiology, Research Institute of the McGill Univ. Health, Montreal, Canada, McGill University Health Center, McMaster University and Juravinski Cancer Centre,